{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(21-22)"],"submitter":["Zhu F"],"funding":["ImmunoGen"],"pubmed_abstract":["<b>Aim:</b> The aim of this research was to evaluate the immunogenicity of mirvetuximab soravtansine (MIRV), an antibody-drug conjugate in patients with folate receptor alpha-positive ovarian cancer across four clinical studies.<b>Materials & methods:</b> An assay was developed and validated for the detection of antidrug antibodies (ADAs) against MIRV. A cell-based method was also developed and validated for the detection of neutralizing anti-MIRV antibodies (NAbs). Both ADAs and NAbs were assessed across four clinical studies in 734 patients.<b>Results:</b> Across studies, MIRV demonstrated low immunogenicity with 7.8% of patients with treatment-emergent ADAs, 7.2% with treatment-unaffected ADAs, and 0.5% with treatment-enhanced ADAs. MIRV trough concentrations were comparable in ADA-nega"],"journal":["Bioanalysis"],"pagination":["1101-1113"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11583603"],"repository":["biostudies-literature"],"pubmed_title":["Assessment of mirvetuximab soravtansine immunogenicity in patients with folate receptor alpha-positive ovarian cancer."],"pmcid":["PMC11583603"],"pubmed_authors":["Tu YP","Zhu F","Sloss C","Wang Y"],"additional_accession":[]},"is_claimable":false,"name":"Assessment of mirvetuximab soravtansine immunogenicity in patients with folate receptor alpha-positive ovarian cancer.","description":"<b>Aim:</b> The aim of this research was to evaluate the immunogenicity of mirvetuximab soravtansine (MIRV), an antibody-drug conjugate in patients with folate receptor alpha-positive ovarian cancer across four clinical studies.<b>Materials & methods:</b> An assay was developed and validated for the detection of antidrug antibodies (ADAs) against MIRV. A cell-based method was also developed and validated for the detection of neutralizing anti-MIRV antibodies (NAbs). Both ADAs and NAbs were assessed across four clinical studies in 734 patients.<b>Results:</b> Across studies, MIRV demonstrated low immunogenicity with 7.8% of patients with treatment-emergent ADAs, 7.2% with treatment-unaffected ADAs, and 0.5% with treatment-enhanced ADAs. MIRV trough concentrations were comparable in ADA-nega","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-04-24T03:25:22.181Z","creation":"2025-04-03T23:56:44.634Z"},"accession":"S-EPMC11583603","cross_references":{"pubmed":["39378056"],"doi":["10.1080/17576180.2024.2407228"]}}